FilingSEC EDGAR8-K
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
· SEC accepted
StagePhase 2 preparation
Filing content
Polaryx Therapeutics announced the appointment of Dr. Will Charlton as Chief Medical Officer, effective September 1, 2026, to strengthen clinical leadership ahead of the planned Q4 2026 SOTERIA Phase 2 trial initiation.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…